Electrophysiologic effects of AHR 10718 on isolated cardiac tissues. 1985

B P Damiano, and H Le Marec, and M R Rosen

We used microelectrode and blood superfusion techniques to study the electrophysiologic effects of a new antiarrhythmic compound, AHR 10718 (N'-(2-(diethylamino)ethyl)-N-(1-methylethyl)-N-(2-(phenylsulfonyl )ethyl)urea,(Z)-butanedioate) on the electrophysiologic properties of canine Purkinje fibers and papillary muscles. AHR 10718 (greater than or equal to 5 X 10(-6) M) induced a use-dependent decrease in Vmax and significantly decreased Purkinje fiber conduction velocity and action potential duration. In addition, membrane responsiveness was depressed and the effective refractory period shortened. The effects of AHR 10718 were not highly dependent on [K+]0. Vmax of ventricular muscle action potentials also was reduced. However, in contrast to Purkinje fibers, ventricular muscle action potentials were significantly prolonged by AHR 10718 (greater than or equal to 5 X 10(-6) M). AHR 10718 had no effect on slow response action potentials induced by isoproterenol and high [K+]0. AHR 10718 significantly decreased normal automaticity, catecholamine-enhanced automaticity, and abnormal automaticity induced by barium or myocardial infarction. It also suppressed triggered activity and reduced delayed afterdepolarization amplitude in ouabain-treated Purkinje fibers and infarcted myocardium. These studies suggest that AHR 10718 may be effective against arrhythmias resulting from conduction disturbances and certain forms of abnormal impulse initiation.

UI MeSH Term Description Entries
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D010210 Papillary Muscles Conical muscular projections from the walls of the cardiac ventricles, attached to the cusps of the atrioventricular valves by the chordae tendineae. Muscle, Papillary,Muscles, Papillary,Papillary Muscle
D010671 Phenylurea Compounds Compounds that include the amino-N-phenylamide structure. Phenylcarbamides,Phenylurea Derivatives,Compounds, Phenylurea,Derivatives, Phenylurea
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D011690 Purkinje Fibers Modified cardiac muscle fibers composing the terminal portion of the heart conduction system. Purkinje Fiber,Fiber, Purkinje,Fibers, Purkinje
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006329 Heart Conduction System An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart. Conduction System, Heart,Conduction Systems, Heart,Heart Conduction Systems,System, Heart Conduction,Systems, Heart Conduction
D000200 Action Potentials Abrupt changes in the membrane potential that sweep along the CELL MEMBRANE of excitable cells in response to excitation stimuli. Spike Potentials,Nerve Impulses,Action Potential,Impulse, Nerve,Impulses, Nerve,Nerve Impulse,Potential, Action,Potential, Spike,Potentials, Action,Potentials, Spike,Spike Potential
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic

Related Publications

B P Damiano, and H Le Marec, and M R Rosen
February 1988, European journal of pharmacology,
B P Damiano, and H Le Marec, and M R Rosen
June 1973, The Journal of pharmacology and experimental therapeutics,
B P Damiano, and H Le Marec, and M R Rosen
April 1983, Journal of molecular and cellular cardiology,
B P Damiano, and H Le Marec, and M R Rosen
October 1994, Journal of cardiovascular pharmacology,
B P Damiano, and H Le Marec, and M R Rosen
November 1987, Journal of cardiovascular pharmacology,
B P Damiano, and H Le Marec, and M R Rosen
September 1990, Anesthesia and analgesia,
B P Damiano, and H Le Marec, and M R Rosen
April 1992, The American journal of cardiology,
B P Damiano, and H Le Marec, and M R Rosen
December 1979, The Journal of pharmacology and experimental therapeutics,
B P Damiano, and H Le Marec, and M R Rosen
May 1985, Journal of the American College of Cardiology,
B P Damiano, and H Le Marec, and M R Rosen
January 1986, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!